Bluebird shares leap after gene therapy seen as cure for blood disorder

(Reuters) - Shares of drug developer bluebird bio Inc shot up on Tuesday, after the company presented data that showed a cure for beta-thalassemia is within reach, prompting several brokerages to raise their price targets on the stock.

via Reuters: Health News Read More Here..